Home » Authors » Brady Huggett

Articles by Brady Huggett

GenVec Plans Merger With Diacrin Through $40M Stock Transaction

April 16, 2003

By Brady Huggett

Not to compare the biotechnology industry - with its blockbuster drugs and groundbreaking science - with a flea market, but there are good deals in this depressed environment if you look around. (BioWorld Today)

Third Acadia, Allergan Deal Has Potential For More Than $32M

April 16, 2003

By Brady Huggett

Third Acadia, Allergan Deal Has Potential For More Than $32M

April 16, 2003

By Brady Huggett

GenVec Plans Merger With Diacrin Through $40M Stock Transaction

April 16, 2003

By Brady Huggett

Not to compare the biotechnology industry - with its blockbuster drugs and groundbreaking science - with a flea market, but there are good deals in this depressed environment if you look around. (BioWorld Today)

Deal With GSK Gives Celgene Multiple Myeloma Drug To Sell

April 15, 2003

By Brady Huggett

Deal With GSK Gives Celgene Multiple Myeloma Drug To Sell

April 15, 2003

By Brady Huggett

Ansata Hits Milestone, Pulls In Second Half Of $5M Series A

April 11, 2003

By Brady Huggett

Ansata Hits Milestone, Pulls In Second Half Of $5M Series A

April 11, 2003

By Brady Huggett

Canadian Companies Inflazyme, GlycoDesign Plan C$12.8M Merger

April 10, 2003

By Brady Huggett

Canadian Companies Inflazyme, GlycoDesign Plan C$12.8M Merger

April 10, 2003

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...